Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by biorunon Sep 29, 2022 3:40pm
125 Views
Post# 34995751

RE:RE:RE:RE:RE:biorun, you loser

RE:RE:RE:RE:RE:biorun, you loserAre you reading ok?

There is a difference between the upfront payment and cash flow to sustain operations without financing. The two are related but the upfront payment is not the only source of money. I also started the day by saying the next few days were an opportunity, not just today.

First principle, nobody knows what the upfront payment is. If you think its going to be enough to make a big difference then you are decieving yourself.

I have said on many occasions that, according to historical information, there is a grant from the French Government to support fluorination chemistry, and as well the upfront payment, whatever that is. Between these two, I would be surprised if they needed additional cash.

I highly doubt R&F will produce additional revenue, but since they were zero for 2 quarters, perhaps that is also possible that they place another order and a little cash accrues there.

I think you haven't been taking the cues here that nobody expects the upfront to be surprising in a positive way. Sleepyhoward even said the other day $1 million. A few smart ones on the German boards say the same thing and have been for months based upon their experiences.

The play here is really to take advantage of the weak hands and buy shares when others are selling. This too shall pass and we will be talking about Anti-aging and Pets deals soon enough.

Lots on the go.
<< Previous
Bullboard Posts
Next >>